Japan Cardiac Resynchronization Therapy Market Overview, 2031

Key Insights

• Japan represents one of the world's most sophisticated Cardiac Resynchronization Therapy (CRT) markets, supported by its universal healthcare system, highly specialized cardiovascular care network, and one of the fastest-aging populations globally. Cardiovascular disease remains the country's second leading cause of death, with heart failure emerging as the predominant cardiac cause of mortality. According to the latest Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) 2025 Heart Failure Guideline, approximately 285,000 heart failure hospitalizations were recorded in Japan during 2023, with an in-hospital mortality rate of 9.1%, reflecting the growing clinical burden associated with advanced heart failure. The increasing proportion of elderly individuals aged 65 years and above continues to expand the population eligible for device-based therapies including Cardiac Resynchronization Therapy.
• Japan's healthcare delivery model places considerable emphasis on early diagnosis, standardized cardiovascular care pathways, and long-term management of chronic diseases under its universal National Health Insurance (NHI) system. Heart failure patients benefit from multidisciplinary management involving cardiologists, electrophysiologists, primary care physicians, rehabilitation specialists, pharmacists, and community healthcare providers. National cardiovascular registries such as the Japanese Registry of All Cardiac and Vascular Diseases (JROAD) together with Diagnosis Procedure Combination (DPC) hospital databases enable continuous monitoring of treatment outcomes, procedural quality, and healthcare utilization across certified cardiovascular centers. These comprehensive data infrastructures facilitate evidence-based patient selection for CRT implantation while supporting nationwide quality improvement initiatives.
• Japan also serves as one of Asia-Pacific's leading centers for cardiovascular research, electrophysiology innovation, and advanced medical device adoption. Clinical practice is guided by the Japanese Circulation Society (JCS) and the Japanese Heart Rhythm Society (JHRS), while regulatory oversight is administered by the Pharmaceuticals and Medical Devices Agency (PMDA) under the Ministry of Health, Labour and Welfare (MHLW). Japan's strong ecosystem of university hospitals, cardiovascular institutes, and clinical research networks enables rapid evaluation of next-generation implantable cardiac technologies including physiologic pacing, remote monitoring systems, artificial intelligence-assisted device optimization, and digital heart failure management platforms. International manufacturers including Medtronic, Abbott, Boston Scientific, BIOTRONIK, and MicroPort CRM maintain significant commercial and clinical collaborations throughout Japan's advanced cardiovascular care network.

Market Outlook

• According to the research report, "Japan Cardiac Resynchronization Therapy Market Outlook, 2031," published by Bonafide Research, the Japan Cardiac Resynchronization Therapy Market is anticipated to add to more than 80 Million by 2026-31.
• Japan's cardiac resynchronization therapy (CRT) market emphasizes evidence-based cardiovascular care within its universal health insurance system, prioritizing patient outcomes over procedural volume. Clinical decisions follow Japanese Circulation Society (JCS) and Japanese Heart Rhythm Society (JHRS) guidelines, ensuring CRT is offered only to appropriately selected heart failure patients despite optimal medical therapy. Multidisciplinary heart failure programs, advanced imaging-guided lead implantation, physiologic pacing, individualized device programming, and structured long-term follow-up collectively support high procedural quality and improved clinical outcomes.

• Digital transformation is strengthening Japan's cardiac rhythm management ecosystem through cloud-based remote monitoring platforms that continuously transmit arrhythmia data, device diagnostics, pacing parameters, and physiological indicators to specialist centers. These technologies enable earlier detection of heart failure deterioration, remote device optimization, and fewer avoidable hospitalizations. Supported by the Ministry of Health, Labour and Welfare (MHLW), expanding telemedicine services and ongoing clinical studies are accelerating digitally connected, long-term heart failure management, particularly in underserved and rural regions.



• Japan's technologically advanced medical device sector benefits from strong collaboration among global manufacturers, leading university hospitals, and cardiovascular research institutions developing next-generation CRT technologies, conduction system pacing, artificial intelligence-assisted optimization, and digital heart failure solutions. A structured reimbursement framework requires approval by the Pharmaceuticals and Medical Devices Agency (PMDA) followed by National Health Insurance (NHI) reimbursement listing through the Ministry of Health, Labour and Welfare, ensuring broad access to clinically validated innovations while maintaining healthcare sustainability.

Market Dynamics

Driver: Rapid population aging and the growing burden of chronic heart failure
Japan's Cardiac Resynchronization Therapy (CRT) market is primarily driven by the country's rapidly aging population and the rising prevalence of chronic heart failure and cardiac conduction disorders. Nearly 30% of Japan's population is aged 65 years or older, increasing the incidence of heart failure, atrial fibrillation, ischemic heart disease, and left bundle branch block (LBBB), key indications for CRT. Improved survival from myocardial infarction, hypertension, and valvular heart disease has expanded the pool of patients progressing to advanced heart failure. Supported by universal National Health Insurance (NHI) coverage and evidence-based guidelines from the Japanese Circulation Society (JCS), eligible patients have broad access to CRT, sustaining long-term market demand.
Challenge: Workforce shortages and regional disparities in advanced electrophysiology services
Although Japan has one of the world's most advanced healthcare systems, access to specialized CRT implantation remains concentrated in major metropolitan and university hospitals. Complex procedures require experienced electrophysiologists, advanced imaging technologies, catheterization laboratories, and multidisciplinary heart failure teams, resources that remain limited in many rural prefectures. Physician shortages, an aging healthcare workforce, and increasing procedural demand continue to place pressure on tertiary cardiovascular centers. Consequently, healthcare providers are prioritizing optimized patient selection, stronger referral networks, telemedicine-supported follow-up, and operational efficiency instead of relying solely on higher implantation volumes.
Trend: Expansion of remote cardiac monitoring and digitally integrated heart failure management
A major trend shaping Japan's CRT market is the rapid adoption of remote cardiac monitoring and digitally integrated heart failure management. Modern CRT devices increasingly transmit device diagnostics, arrhythmia episodes, thoracic impedance, pacing performance, battery status, and other physiological data to specialist centers, enabling early detection of heart failure deterioration and remote device optimization. Supported by the Ministry of Health, Labour and Welfare (MHLW) through Medical DX and telemedicine initiatives, hospitals are also adopting artificial intelligence-assisted device programming, cloud-based cardiovascular platforms, predictive analytics, and conduction system pacing to improve long-term outcomes and healthcare efficiency.

Policies

• Pharmaceuticals and Medical Devices Act (PMD Act): Cardiac Resynchronization Therapy (CRT) devices in Japan are regulated under the Pharmaceuticals and Medical Devices Act (PMD Act). High-risk implantable devices, including CRT-P and CRT-D systems, require rigorous review by the Pharmaceuticals and Medical Devices Agency (PMDA), covering clinical evidence, safety, manufacturing quality, and post-market surveillance before approval by the Ministry of Health, Labour and Welfare (MHLW).
• National Health Insurance (NHI) Reimbursement System: Japan's universal National Health Insurance (NHI) system provides reimbursement for clinically indicated CRT implantation, ensuring broad patient access. Following PMDA approval, reimbursement prices are determined by the Central Social Insurance Medical Council (Chuikyo). Regular reimbursement revisions encourage adoption of innovative, clinically effective technologies while maintaining the financial sustainability of Japan's publicly funded healthcare system.
• Diagnosis Procedure Combination (DPC) Payment System: CRT implantation in many acute-care and university hospitals is reimbursed through Japan's Diagnosis Procedure Combination (DPC) payment system. The framework promotes standardized clinical pathways, efficient inpatient care, and evidence-based resource utilization, enabling hospitals to deliver complex cardiovascular procedures while improving treatment quality and controlling healthcare expenditure.
• Japanese Circulation Society (JCS) and JHRS Clinical Guidelines: CRT implantation follows recommendations issued by the Japanese Circulation Society (JCS), Japanese Heart Rhythm Society (JHRS), and Japanese Heart Failure Society (JHFS). These guidelines standardize patient selection using left ventricular ejection fraction, QRS duration, NYHA functional class, and guideline-directed medical therapy, ensuring appropriate and evidence-based use of CRT across Japan.
• Post-Market Surveillance and National Cardiovascular Registries: Japan operates a robust post-market surveillance system for high-risk implantable devices through the PMDA, requiring adverse event reporting and continuous safety monitoring. National registries, including JROAD, collect real-world cardiovascular data to evaluate CRT outcomes, support quality improvement, and provide evidence for future reimbursement decisions and clinical guideline updates.

Segment Analysis

Japan Cardiac Resynchronization Therapy Market By Product Type • CRT-D (Cardiac Resynchronization Therapy Defibrillator): CRT-D is the dominant product segment in Japan's CRT market, primarily used for heart failure patients with reduced LVEF and increased risk of ventricular arrhythmias or sudden cardiac death. Its adoption is supported by advanced electrophysiology centers, university hospitals, and guideline-based patient selection under recommendations from the Japanese Circulation Society (JCS) and Japanese Heart Rhythm Society (JHRS).



• CRT-D Technology Advancement: Demand for next-generation CRT-D systems is increasing in Japan due to advanced features such as MRI compatibility, quadripolar leads, improved battery performance, remote monitoring, and enhanced arrhythmia detection. Japanese hospitals are increasingly adopting image-guided implantation, individualized programming, and digital follow-up solutions to improve treatment outcomes and optimize long-term heart failure management.

• CRT-P (Cardiac Resynchronization Therapy Pacemaker): CRT-P remains a significant segment, particularly among Japan's rapidly growing elderly and frail patient population. It is commonly selected for patients who require ventricular resynchronization but have lower risk of sudden cardiac death. Treatment decisions consider age, comorbidities, life expectancy, and quality-of-life factors, reflecting Japan's patient-centered approach to heart failure care.

• Market Support and Competitive Landscape: Japan's CRT market growth is supported by the National Health Insurance (NHI) reimbursement system, PMDA regulatory approval, and structured hospital procurement processes. Leading companies such as Medtronic, Abbott, Boston Scientific, BIOTRONIK, and MicroPort CRM continue expanding their presence through innovative devices, clinical collaborations, and remote monitoring technologies, strengthening Japan's advanced cardiac rhythm management ecosystem.
Japan Cardiac Resynchronization Therapy Market By Application
• Heart Failure Management: Heart failure management is the largest application segment in Japan's CRT market, driven by the country's aging population and increasing prevalence of chronic heart failure. CRT is mainly used for patients with reduced left ventricular ejection fraction (LVEF), ventricular conduction abnormalities, and persistent symptoms despite optimal medical therapy. Adoption is supported by Japanese Circulation Society (JCS) guidelines and multidisciplinary heart failure care programs.
• Advanced Heart Failure Care and Remote Monitoring: Japan's hospitals increasingly integrate CRT into comprehensive heart failure management programs involving cardiologists, electrophysiologists, rehabilitation teams, and primary care providers. Advanced diagnostic tools such as echocardiography, cardiac MRI, and electrocardiography support accurate patient selection. Remote monitoring technologies are expanding, enabling early detection of worsening heart failure, device optimization, and reduced hospital admissions, particularly among elderly patients.
• Arrhythmia Management: Arrhythmia management is another major application area, supported by Japan's rising burden of conduction disorders, ventricular arrhythmias, and cardiomyopathies. CRT-D systems are widely used for patients requiring both resynchronization and protection against sudden cardiac death. Japanese electrophysiology centers combine CRT procedures with catheter ablation, three-dimensional mapping, and personalized rhythm management strategies to improve outcomes.
• Emerging Applications and Future Technologies: Japan continues to evaluate advanced pacing strategies, including His bundle pacing and left bundle branch area pacing, to improve physiological cardiac activation. Additional applications include CRT upgrades, pacing-induced cardiomyopathy, and complex heart failure cases. Academic institutions and cardiovascular centers are also exploring artificial intelligence-based programming, digital health platforms, and personalized device management to enhance CRT effectiveness.
Japan Cardiac Resynchronization Therapy Market By End User
• Hospitals: Hospitals represent the largest end-user segment in Japan's CRT market due to the complexity of implantation procedures and the need for specialized infrastructure. University hospitals, tertiary cardiovascular centers, and national medical institutions perform most CRT procedures using advanced electrophysiology laboratories, imaging systems, and multidisciplinary heart failure teams. These facilities also provide post-implantation monitoring and long-term device management.
• Cardiac Specialty Centers: Specialized cardiovascular hospitals and heart failure centers play an increasing role in Japan's CRT ecosystem by managing complex patients requiring advanced electrophysiology expertise. These centers provide comprehensive services, including device selection, lead implantation, programming, rehabilitation, and remote monitoring. Their concentration of expertise supports improved clinical outcomes and efficient management of high-risk heart failure patients.
• Academic and Research Institutions: Japan's leading academic hospitals and cardiovascular research centers contribute to CRT innovation through clinical studies, national registries, and evaluation of emerging technologies. Institutions such as the National Cerebral and Cardiovascular Center (NCVC) and major universities support research on conduction system pacing, artificial intelligence-assisted optimization, and next-generation cardiac rhythm management solutions.
• Other Healthcare Facilities: Rehabilitation hospitals, outpatient cardiology clinics, and community healthcare providers support long-term CRT follow-up and chronic heart failure management. With Japan's focus on integrated community care, remote monitoring and telemedicine are becoming increasingly important for maintaining continuity of care, especially for elderly patients living outside major urban medical centers.

Market Landscape and Commercial Ecosystem

• Japan's Cardiac Resynchronization Therapy (CRT) market benefits from its advanced healthcare infrastructure, universal health insurance system, strong regulatory framework, and high adoption of innovative cardiovascular technologies. Global companies such as Medtronic, Abbott, Boston Scientific, BIOTRONIK, and MicroPort CRM maintain strong market presence through collaborations with Japanese hospitals, physician training programs, and clinical research initiatives focused on next-generation CRT systems.
• Japan's CRT ecosystem is supported by strict regulatory oversight from the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW), ensuring device safety and clinical effectiveness. Leading institutions, including the National Cerebral and Cardiovascular Center (NCVC) and major university hospitals, contribute to research on conduction system pacing, artificial intelligence-based optimization, and remote monitoring technologies.
• The Japanese CRT market is evolving toward digitally integrated and outcome-focused cardiovascular care. Remote monitoring, cloud-based platforms, advanced imaging-guided implantation, and personalized programming are improving patient management and reducing hospitalizations. Growth will be driven by an aging population, rising heart failure burden, and technological innovation, while challenges such as healthcare costs, specialist shortages, and regional disparities will encourage efficient, value-based care models.

Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cardiac Resynchronization Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• CRT-D (Cardiac Resynchronization Therapy Defibrillator)
• CRT-P (Cardiac Resynchronization Therapy Pacemaker)

By Application
• Heart Failure Management
• Arrhythmia Management
• Others

By End-User
• Hospitals
• Cardiac Specialty Centers
• Others